secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2026-07-08T11:17:42+00:00
Accession:  0001193125-26-297992
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences appoints Jeremy Bender to Board of Directors; updates director compensation policy
--------------------------------------------------------------------------------

- Jeremy Bender, Ph.D., M.B.A., appointed as Class II director effective July 7, 2026; term expires at 2029 annual meeting.
- Bender appointed to Compensation Committee and Nominating and Corporate Governance Committee.
- Received initial option award for 60,000 shares and RSU award for 30,000 shares, vesting over three years.
- Board amended Non-Employee Director Compensation Policy on June 11, 2026, increasing initial option award from 34,000 to 60,000 shares and annual option award from 17,000 to 30,000 shares.
- Bender previously CEO of Day One Biopharmaceuticals, led acquisition by Servier for ~$2.5B in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000119312526297992/0001193125-26-297992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000119312526297992/aura-20260703.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-297992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer